NB1002 causes cancer cell death but not normal skin cells
Colon Cancer Cells
Normal Skin Fibroblasts
NB1002 can effectively inhibit HRD tumour growth in preclinical animal experiments without any side effects on the animals
Based on the preclinical data, NB1002 could effectively instigating synthetic lethality via R-Loop and Transcription Replication Conflict in Homologous Recombination Deficiency (HRD) cancers (E.g Triple Negative BRCA (-/-) Breast Cancer) .
As our therapeutics are effective on a spectrum of cancers exhibiting HRD, it offers an opportunity to revolutionize the approach towards cancer treatment. For HRD or BRCA mutation carriers (High Risk Group), this mechanism offers a prophylactic barrier, pre-emptively targeting potential malignant transformations.
Efficacy & Mode of Action
Highly Effective to Treat Tumor in Preclinical Trials
NB1002 instigating synthetic lethality in Homologous Recombination Deficiency (HRD) cancers
Intellectual property
3 PCT Patent Filed (National Phase: USA, EU, China, Japan, India, Israel, Australia and Singapore)
ADMET
In 2024
Clinical Trials
In 2025